Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Phase 2TerminatedNCT00122512

FHI 360500 enrolled

Overview

This Phase 2a study involving Tenofovir Disoproxil Fumarate (TDF) will provide extended safety data for high-risk men. Secondarily, the study will assess the feasibility of conducting the trial and evaluate the preliminary effectiveness of TDF 300 mg as an HIV prevention method when taken once a day.

TDF has been selected for investigation as prophylaxis against HIV in high-risk men because of its unique pharmacologic profile. In addition to the convenience of being a once daily single tablet, TDF's safety profile is comparable to placebo among HIV infected persons, it has striking anti-HIV potency, and it has low potential for selection of resistant viruses. TDF is cleared from the body by the kidneys and is not metabolized by the liver. Therefore, TDF has limited potential to have pharmacokinetic interactions with other hepatically metabolized drugs. Each of these properties is necessary given the realities of the intended target populations. Moreover, initial prevention studies in simian models have provided encouraging results. Finally, the drug's sponsor is supportive of investigating the potential use of TDF as a preventive, as well as therapeutic agent, will provide TDF for the study, and is willing to make a good faith effort to make TDF available for public health use should it prove to be effective for HIV prevention.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

500

Conditions

HIV Infections

Interventions

Tenofovir Disoproxil FumarateDRUG

Eligibility

Sex: MALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

* Be willing and able to give informed consent * Be 18 years or older * Be willing to use study product as directed * Be willing to adhere to follow-up schedule * Be willing to participate in the study for up to 12 months * Be in general good health (no active, serious infections that require parenteral antibiotics, no active clinically significant medical conditions, including heart disease, diabetes, asthma, alcoholism, and cancer) * Meet at least one of these three high risk criteria: \*Sex with sex worker/bar girl in last 3 months; * Sex with 2 or more women in last 3 months; * Sexually transmitted disease (STD) in last 3 months * Have absence of HIV antibodies by rapid test (at screening and enrollment visit) * Have absence of hepatitis B (HB) surface antigen (sAg) * Have adequate renal function (serum creatinine \<1.5 mg/dL) * Have adequate liver function (hepatic transaminases (ALT \<54 U/L and AST\<46 U/L) * Have adequate serum phosphorus (\>2.2 mg/dL) * Not be intending to relocate out of the area for the duration of the study participation and does not have a job or other obligations that may require long absences from the area * Not be receiving an experimental HIV vaccine

Locations (1)

UNC Project, Kamuzu Central Hospital

Lilongwe, Malawi

Outcomes

Primary Outcomes

To evaluate the extended safety of TDM 300mg daily among HIV-uninfected men

Secondary Outcomes

To evaluate the feasibility (i.e. accrual, retention, adherence, change in behavior) of conducting a large scale trial of TDF for HIV prevention in men recruited from a resource-limited setting

To assess the preliminary effectiveness of TDF in preventing HIV infection among men at high risk for HIV

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.